Stand By Your Biotech: Amgen's Loyal Legions

On this particularly edgy market, no stock appears to be quite secure. If the Street is given some reason--almost any reason--to dump a stock, it hits the eject button pronto. That's what sent Amgen, the once high-flying premier biotech, crashing 10 points, or 20%, to 37 a share on Feb. 25.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.